Inhibrx Biosciences, Inc. (INBX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $92.74: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 11.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate... Read more
Sell if holding. Engine safety override at $92.74: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 11.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Inhibrx Biosciences, Inc.
Latest news
- NEWS Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDU — benzinga Jun 15, 2026 positive
- NEWS Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate — benzinga May 14, 2026 negative
- NEWS Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study — benzinga May 11, 2026 positive
- NEWS Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC — benzinga May 11, 2026 positive
- NEWS 12 Health Care Stocks Moving In Friday's After-Market Session — benzinga May 8, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.9% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $92.74: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 11.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $86.25. Score 4.5/10, moderate confidence.
Take-profit target: $235.88 (+154.3% upside). Prior stop was $86.25. Stop-loss: $86.25.
Quality below floor (1.8 < 4.0).
Inhibrx Biosciences, Inc. trades at a P/E of N/A (forward -33.0). TrendMatrix value score: 5.0/10. Verdict: Sell.
9 analysts cover INBX with a consensus score of 4.1/5. Average price target: $278.
What does Inhibrx Biosciences, Inc. do?Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic...
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.